Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


European Perspectives in AML from EHA 25

Published on: 23.06.2020, 30 min.

In this webinar, Prof. Dr. Nigel Russel, MD and Prof. Dr. Gert Ossenkoppele discuss two practice changing studies on AML.

Study 1 summarised by Prof. Dr. Nigel Russell MD

(S144) THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IS WELL-TOLERATED AND EFFECTIVE IN AML PATIENTS: PHASE 1B RESULTS

Study 2 summarised by Prof. Dr. Gert Ossenkoppele

(LB2601) A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VENETOCLAX WITH AZACITIDINE VS AZACITIDINE IN TREATMENT-NAÏVE PATIENTS WITH ACUTE MYELOID LEUKEMIA INELIGIBLE FOR INTENSIVE THERAPY-VIALE-A

 

The webinar was independently produced and paid for by the MEDtalks Group of Companies.